Products
Casdozokitug Biosimilar Monoclonal Antibody (IL-27) for Research
Cat No.: GMP-Bios-INN-1124
Anti-IL27 therapeutic antibody (Pre-made Casdozokitug biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Casdozokitug (development code SRF 388) is a monoclonal antibody targeting interleukin-27 (IL27). It is developed by Surface Oncology for solid tumours, hepatocellular carcinoma. It is in Phase II clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1124-1mg | 1mg | 3090 |
| GMP-Bios-INN-1124-10mg | 10mg | |
| GMP-Bios-INN-1124-100mg | 100mg | |
| GMP-Bios-INN-1124-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Casdozokitug biosimilar, Whole mAb, Anti-IL27 Antibody: Anti-IL-17D/IL17D/IL27/Interleukin-17D therapeutic antibody |
| INN Name | Casdozokitug |
| Target | IL27 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | 7zxk:HL:JI |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2022 |
| Year Recommended | 2023 |
| Companies | Surface Oncology |
| Conditions Approved | na |
| Conditions Active | Solid tumours;Hepatocellular carcinoma |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | Artificial human yeast display library |
